result ema/co methotrex actinomycin cyclophosphamid vincristin regimen high risk gestat trophoblast tumour object efficaci toxic surviv patient high risk gtt ema/co regimen methotrex actinomycin cyclophosphamid vincristine/oncovin design open non-random studi consecut patient chare cross hospit set trophoblast diseas centr london teach hospit subject consecut patient high risk gtt ema/co regimen patient prior chemotherapi chemotherapi main outcom measur surviv treatment failur toxic result patient prior chemotherapi remiss overal surviv patient patient prior chemotherapi extens diseas week chemotherapi complet partial respons rate ema/co chemotherapi addit cisplatin drug resist surgeri salvag surgeri complet remiss relaps ema/co chemotherapi uncommon surviv good chemotherapi and/or surgeri patient sustain remiss complic ema/co chemotherapi accept myelosuppress dose-limit late sequela uncommon menstruat month fetal abnorm subsequ pregnanc patient therapy-induc acut myeloid leukaemia conclus present ema/co chemotherapi treatment choic patient high risk gtt toxic predict revers patient drug resist salvag surgeri import futur develop dose intensif addit haemopoiet growth factor diagnosi separ gestat non-gest trophoblast tumour 